An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizumab study (IMBRELLA B)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506184-34-00

Acronym

BO40729

Enrollment

104

Registered

2024-07-08

Start date

2019-08-09

Completion date

Unknown

Last updated

2025-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Malignancies

Brief summary

Patients who are deriving clinical benefit from the treatment with atezolizumab-based therapy and/or comparator agent(s) according to investigator assessment.

Interventions

DRUGAlecensa 150 mg hard capsules

DRUGSutent 50 mg hard capsules

DRUGRO7047650

DRUGALIMTA 500 mg powder for concentrate for solution for infusion

DRUGCotellic

DRUGAlectinib (Alecensa)

DRUGZelboraf

DRUGPaclitaxel 6 mg/ml Concentrate for Solution for Infusion

DRUGSutent 12.5 mg hard capsules

DRUGRO7250726

DRUGVenclexta

DRUGVenclyxto

DRUGTecentriq 1 200 mg concentrate for solution for infusion

DRUGSutent 25 mg hard capsules

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Patients who are deriving clinical benefit from the treatment with atezolizumab-based therapy and/or comparator agent(s) according to investigator assessment.	—

Countries

Belgium, Czechia, France, Germany, Greece, Hungary, Latvia, Poland, Romania, Slovakia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026